Why the study?
Degenerated saphenous vein grafts carry higher risk of no-reflow, and while CHA2DS2-VASc predicts no-reflow in ACS, its association in elective SVG PCI required evaluation.
Does the CHA2DS2-VASc score predict no-reflow and short-term mortality in patients with SVG undergoing elective PCI?
Does the CHA2DS2-VASc score predict no-reflow and short-term mortality in patients with SVG undergoing elective PCI?
This study evaluates the utility of the CHA2DS2-VASc score as a predictor for no-reflow and short-term mortality in patients undergoing elective PCI for saphenous vein grafts.
Answers are grounded in this paper and cite their sources.
CHA2DS2-VASc may aid risk stratification in elective SVG PCI; hypothesis-generating and requires prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kanal et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: